Abstract 249: Stationary Signal and Flow Velocity Assessment by MRI of a New Nitinol Nanocomposite Polymer Stent-Graft
Objective: To assess MRI compatibility and suitability of a new sutureless stent-graft made from Nitinol bonded to nanocomposite polymer (NP).
1. Using MRI and Magnevist contrast, isotropic 3D T1-weighted FFE images of NP stent-graft were acquired to observe artefacts and stationary signal attenuation. Average signal magnitude was calculated. Medtronic ValiantTM was used as control.
2. In second stage, steady flow phantom was setup for flow-encoded MRI signal assessment of both stent-grafts. Baseline values were obtained by velocity measurements without stent-graft using identical settings. 2D through-plane phase contrast images were acquired and average velocity and amount of flow (flux) were calculated.
Results: On static assessment of NP and ValiantTM stent-grafts no significant image artefacts were seen. The signal inside and outside the ValiantTM stent-graft was 644.2(SD 36.2) and 659.6(SD 85.8) respectively. The signal attenuation for this device was 2.39%. The signal inside and outside the NP stent graft was 1561.7(SD 31.2) and 1595.5(SD 40.8) respectively with comparable signal attenuation of 2.16%. In MRI velocity attenuation study, steady flow phantom was set at mean volume of 105.3 ml and mean velocity of 79.5 cm/sec. Flux measured in ValiantTM stent-graft was 102±2.27 ml/sec with no significant difference to baseline (104±1.98 ml/sec; P=0.892). Similarly flux for NP stent-graft at mean stroke volume 104.4 ml and mean velocity of 92.3 cm/sec showed no difference to baseline (99.8±2.4 vs. 104±0.96 ml/sec; P=0.176). There was no significant difference in flux between Medtronic and NP stent-grafts (102±2.27 vs. 99.8±2.4 ml/sec; P=0.328).
Conclusion: NP stent-graft does not display any material-induced artefacts on MRI. On flow assessment, signal attenuation is comparable with the commercial device. These properties are important in developing this stent-graft, compliant, durable, visco-elastic, biocompatible and anti-thrombogenic, for future clinical use.
- © 2012 by American Heart Association, Inc.